Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has licensed its ADC technology to BigHat Biosciences Inc.   BigHat will combine Synaffix technology with its ML antibody design platform for the development of a new ADC pipeline program.   Under the terms of the agreement, BigHat will receive target-specific access to Synaffix’s late-clinical stage, sit...